Patents Assigned to NGM Biopharmaceuticals, Inc.
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 9550819
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: January 24, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
  • Compositions comprising variants and fusions of FGF19 polypeptides
    Patent number: 9290557
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 22, 2016
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
    Patent number: 9273107
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 1, 2016
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20160045565
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 26, 2013
    Publication date: February 18, 2016
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Lei LING, Jian LUO
  • GDF15 mutein polypeptides
    Patent number: 9161966
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: October 20, 2015
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9089525
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 28, 2015
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
    Patent number: 8951966
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 10, 2015
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin A. Lindhout
  • USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES
    Publication number: 20140243266
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 28, 2014
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Lei LING, Jian Luo
  • Compositions and Methods for Treatment of Metabolic Disorders and Diseases
    Publication number: 20140194352
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 10, 2014
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20140154271
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: May 31, 2012
    Publication date: June 5, 2014
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Maria Deato, Hong Yang, Daniel David Kaplan
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20140099295
    Abstract: Compositions and methods for modulating levels of PLA2G12A are provided. Methods for treating various conditions, such as conditions that are associated with or that result in reduced muscle function and/or muscle mass, are provided. Methods for modulating glucose and/or insulin levels in glucose metabolism disorders are provided.
    Type: Application
    Filed: April 30, 2012
    Publication date: April 10, 2014
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Hui Tian, Daniel David Kaplan, Jun Zhang, Maria Deato
  • Methods of treating glucose metabolism disorders
    Patent number: 8609612
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: December 17, 2013
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan
  • Methods of treating glucose metabolism disorders
    Patent number: 8551944
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 8, 2013
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130216546
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided.
    Type: Application
    Filed: December 14, 2012
    Publication date: August 22, 2013
    Applicant: NGM BIOPHARMACEUTICALS, INC.
    Inventor: NGM Biopharmaceuticals, Inc.
  • Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss
    Publication number: 20130216537
    Abstract: Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided.
    Type: Application
    Filed: December 14, 2012
    Publication date: August 22, 2013
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventor: NGM Biopharmaceuticals, Inc.
  • Methods of Treating Glucose Metabolism Disorders
    Publication number: 20130130975
    Abstract: Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
    Type: Application
    Filed: April 15, 2011
    Publication date: May 23, 2013
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Zhaodan Cao, Yarong Lu, Daniel David Kaplan, Peng Zhang
  • COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES
    Publication number: 20130023474
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 24, 2013
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: LEI LING, DARRIN A. LINDHOUT